SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices with advanced pharmaceuticals, announced today the superiority of the Elixir DESyne stent compared to the control Endeavor stent in the primary endpoint of the EXCELLA II randomized clinical trial.
